Cargando…
A new antibiotic with potent activity targets MscL
The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430313/ https://www.ncbi.nlm.nih.gov/pubmed/25649856 http://dx.doi.org/10.1038/ja.2015.4 |
_version_ | 1782371168300302336 |
---|---|
author | Iscla, Irene Wray, Robin Blount, Paul Larkins-Ford, Jonah Conery, Annie L Ausubel, Frederick M Ramu, Soumya Kavanagh, Angela Huang, Johnny X Blaskovich, Mark A Cooper, Matthew A Obregon-Henao, Andres Orme, Ian Tjandra, Edwin S Stroeher, Uwe H Brown, Melissa H Macardle, Cindy van Holst, Nick Ling Tong, Chee Slattery, Ashley D Gibson, Christopher T Raston, Colin L Boulos, Ramiz A |
author_facet | Iscla, Irene Wray, Robin Blount, Paul Larkins-Ford, Jonah Conery, Annie L Ausubel, Frederick M Ramu, Soumya Kavanagh, Angela Huang, Johnny X Blaskovich, Mark A Cooper, Matthew A Obregon-Henao, Andres Orme, Ian Tjandra, Edwin S Stroeher, Uwe H Brown, Melissa H Macardle, Cindy van Holst, Nick Ling Tong, Chee Slattery, Ashley D Gibson, Christopher T Raston, Colin L Boulos, Ramiz A |
author_sort | Iscla, Irene |
collection | PubMed |
description | The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the bacteria-specific mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are potentially important therapeutics against antibiotic-resistant bacterial infections. |
format | Online Article Text |
id | pubmed-4430313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44303132015-08-07 A new antibiotic with potent activity targets MscL Iscla, Irene Wray, Robin Blount, Paul Larkins-Ford, Jonah Conery, Annie L Ausubel, Frederick M Ramu, Soumya Kavanagh, Angela Huang, Johnny X Blaskovich, Mark A Cooper, Matthew A Obregon-Henao, Andres Orme, Ian Tjandra, Edwin S Stroeher, Uwe H Brown, Melissa H Macardle, Cindy van Holst, Nick Ling Tong, Chee Slattery, Ashley D Gibson, Christopher T Raston, Colin L Boulos, Ramiz A J Antibiot (Tokyo) Original Article The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the bacteria-specific mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are potentially important therapeutics against antibiotic-resistant bacterial infections. Nature Publishing Group 2015-07 2015-02-04 /pmc/articles/PMC4430313/ /pubmed/25649856 http://dx.doi.org/10.1038/ja.2015.4 Text en Copyright © 2015 Japan Antibiotics Research Association http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Iscla, Irene Wray, Robin Blount, Paul Larkins-Ford, Jonah Conery, Annie L Ausubel, Frederick M Ramu, Soumya Kavanagh, Angela Huang, Johnny X Blaskovich, Mark A Cooper, Matthew A Obregon-Henao, Andres Orme, Ian Tjandra, Edwin S Stroeher, Uwe H Brown, Melissa H Macardle, Cindy van Holst, Nick Ling Tong, Chee Slattery, Ashley D Gibson, Christopher T Raston, Colin L Boulos, Ramiz A A new antibiotic with potent activity targets MscL |
title | A new antibiotic with potent activity targets MscL |
title_full | A new antibiotic with potent activity targets MscL |
title_fullStr | A new antibiotic with potent activity targets MscL |
title_full_unstemmed | A new antibiotic with potent activity targets MscL |
title_short | A new antibiotic with potent activity targets MscL |
title_sort | new antibiotic with potent activity targets mscl |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430313/ https://www.ncbi.nlm.nih.gov/pubmed/25649856 http://dx.doi.org/10.1038/ja.2015.4 |
work_keys_str_mv | AT isclairene anewantibioticwithpotentactivitytargetsmscl AT wrayrobin anewantibioticwithpotentactivitytargetsmscl AT blountpaul anewantibioticwithpotentactivitytargetsmscl AT larkinsfordjonah anewantibioticwithpotentactivitytargetsmscl AT coneryanniel anewantibioticwithpotentactivitytargetsmscl AT ausubelfrederickm anewantibioticwithpotentactivitytargetsmscl AT ramusoumya anewantibioticwithpotentactivitytargetsmscl AT kavanaghangela anewantibioticwithpotentactivitytargetsmscl AT huangjohnnyx anewantibioticwithpotentactivitytargetsmscl AT blaskovichmarka anewantibioticwithpotentactivitytargetsmscl AT coopermatthewa anewantibioticwithpotentactivitytargetsmscl AT obregonhenaoandres anewantibioticwithpotentactivitytargetsmscl AT ormeian anewantibioticwithpotentactivitytargetsmscl AT tjandraedwins anewantibioticwithpotentactivitytargetsmscl AT stroeheruweh anewantibioticwithpotentactivitytargetsmscl AT brownmelissah anewantibioticwithpotentactivitytargetsmscl AT macardlecindy anewantibioticwithpotentactivitytargetsmscl AT vanholstnick anewantibioticwithpotentactivitytargetsmscl AT lingtongchee anewantibioticwithpotentactivitytargetsmscl AT slatteryashleyd anewantibioticwithpotentactivitytargetsmscl AT gibsonchristophert anewantibioticwithpotentactivitytargetsmscl AT rastoncolinl anewantibioticwithpotentactivitytargetsmscl AT boulosramiza anewantibioticwithpotentactivitytargetsmscl AT isclairene newantibioticwithpotentactivitytargetsmscl AT wrayrobin newantibioticwithpotentactivitytargetsmscl AT blountpaul newantibioticwithpotentactivitytargetsmscl AT larkinsfordjonah newantibioticwithpotentactivitytargetsmscl AT coneryanniel newantibioticwithpotentactivitytargetsmscl AT ausubelfrederickm newantibioticwithpotentactivitytargetsmscl AT ramusoumya newantibioticwithpotentactivitytargetsmscl AT kavanaghangela newantibioticwithpotentactivitytargetsmscl AT huangjohnnyx newantibioticwithpotentactivitytargetsmscl AT blaskovichmarka newantibioticwithpotentactivitytargetsmscl AT coopermatthewa newantibioticwithpotentactivitytargetsmscl AT obregonhenaoandres newantibioticwithpotentactivitytargetsmscl AT ormeian newantibioticwithpotentactivitytargetsmscl AT tjandraedwins newantibioticwithpotentactivitytargetsmscl AT stroeheruweh newantibioticwithpotentactivitytargetsmscl AT brownmelissah newantibioticwithpotentactivitytargetsmscl AT macardlecindy newantibioticwithpotentactivitytargetsmscl AT vanholstnick newantibioticwithpotentactivitytargetsmscl AT lingtongchee newantibioticwithpotentactivitytargetsmscl AT slatteryashleyd newantibioticwithpotentactivitytargetsmscl AT gibsonchristophert newantibioticwithpotentactivitytargetsmscl AT rastoncolinl newantibioticwithpotentactivitytargetsmscl AT boulosramiza newantibioticwithpotentactivitytargetsmscl |